Market Research Logo

Trans Activator Of Transcription (Tat) - Pipeline Review, H2 2016

Trans Activator Of Transcription (Tat) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Trans Activator Of Transcription (Tat) - Pipeline Review, H2 2016’, provides in depth analysis on Trans Activator Of Transcription (Tat) targeted pipeline therapeutics.

The report provides comprehensive information on the Trans Activator Of Transcription (Tat), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Trans Activator Of Transcription (Tat) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.
  • Updated report will be delivered in 48 hours of order confirmation.
Scope
  • The report provides a snapshot of the global therapeutic landscape for Trans Activator Of Transcription (Tat)
  • The report reviews Trans Activator Of Transcription (Tat) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Trans Activator Of Transcription (Tat) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Trans Activator Of Transcription (Tat) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Trans Activator Of Transcription (Tat) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Trans Activator Of Transcription (Tat)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Trans Activator Of Transcription (Tat) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Trans Activator Of Transcription (Tat) Overview
Therapeutics Development
Trans Activator Of Transcription (Tat) - Products under Development by Stage of Development
Trans Activator Of Transcription (Tat) - Products under Development by Therapy Area
Trans Activator Of Transcription (Tat) - Products under Development by Indication
Trans Activator Of Transcription (Tat) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Trans Activator Of Transcription (Tat) - Products under Development by Companies
Trans Activator Of Transcription (Tat) - Products under Development by Universities/Institutes
Trans Activator Of Transcription (Tat) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Trans Activator Of Transcription (Tat) - Companies Involved in Therapeutics Development
Akshaya Bio Inc
Biosantech SA
Cannabis Science Inc
Trans Activator Of Transcription (Tat) - Drug Profiles
CSTATI-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HIV-1 vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit Tat and Rev for HIV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Trans Activator Of Transcription (Tat) - Dormant Projects
Trans Activator Of Transcription (Tat) - Discontinued Products
Trans Activator Of Transcription (Tat) - Featured News & Press Releases
Jun 08, 2016: Improving the Effect of HIV Drugs by Use of the Tat Vaccine
Mar 15, 2016: Publication in Retrovirology of the results of Biosantech's phase IIA clinical trial for the anti-HIV candidate vaccine
Jul 29, 2015: Cannabis Science Signs Gary Blick, MD and Proceeds With CS-TATI-1 for HIV and Kaposi Sarcoma Drug Development Program
Jan 02, 2015: HIV vaccines should avoid viral target cells, primate model study suggests
Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I
Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma
Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma
Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Akshaya Bio Inc, H2 2016
Pipeline by Biosantech SA, H2 2016
Pipeline by Cannabis Science Inc, H2 2016
Dormant Projects, H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report